LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Acquires Microfluidic Tools and Impedence Flow Cytometer Developer Cellix Limited

By LabMedica International staff writers
Posted on 22 Jun 2023
Print article
Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)
Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)

Randox Laboratories (Crumlin, UK), a global diagnostics company and developer of diagnostic biochips, has completed its acquisition of Cellix Limited (Dublin, Ireland), a developer of microfluidic tools and impedance flow cytometers for cell analysis.

Randox provides innovative diagnostic solutions for a wide range of sectors including hospitals, clinical and research laboratories, food testing, forensic toxicology, veterinary labs, and life sciences. Cellix supplies microfluidic tools and impedance flow cytometers for cell analysis and sorting to customers in life science research, cell and gene therapy discovery, development, and manufacturing. Recently, Cellix introduced its first flow cytometry product, the Inish Analyzer. This microfluidic impedance-based flow cytometer is designed for cell counting, cell viability assessment, and cell membrane analysis for transfection efficiencies. With the acquisition of Cellix, Randox has extended its technical proficiency into the benchtop flow cytometry area, reaffirming its commitment to personalized medicine and improving preventative healthcare.

“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said Dr Peter FitzGerald, Managing Director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”

“Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community,” added Vivienne Williams, CEO of Cellix. “Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”

Related Links:
Randox Laboratories
Cellix Limited

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.